A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 4, 2021

Primary Completion Date

November 30, 2028

Study Completion Date

March 30, 2029

Conditions
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma
Interventions
DRUG

KIN-2787

KIN-2787 will be administered orally twice daily in 28-day cycles

DRUG

KIN-2787 and binimetinib

Continuous and Ramp-Up cohorts: KIN-2787 (exarafenib) and binimetinib will be administered orally twice daily in 28-day cycles Intermittent Cohort: KIN-2787 will be administered orally twice daily and binimetinib will be administered twice daily for 5 days on, 2 days off for 28-day cycles

Trial Locations (36)

2065

RECRUITING

Melanoma Institute Australia, Wollstonecraft

2298

RECRUITING

Calvary Mater Hospital Newcastle, Waratah

4215

RECRUITING

Tasman Health Care, Southport

6009

RECRUITING

Linear Clinical Research, Perth

10016

RECRUITING

NYU Langone, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

28050

RECRUITING

START Madrid, Madrid

29009

RECRUITING

Hospital General Gregorio Marañón, Madrid

32827

RECRUITING

Sarah Cannon Research Institute - Florida Cancer Specialists, Orlando

37203

RECRUITING

Sarah Cannon Research Institute-Tennessee Oncology, Nashville

44195

RECRUITING

Cleveland Clinic, Cleveland

90095

RECRUITING

UCLA, Los Angeles

92093

RECRUITING

University of California San Diego, Moores Cancer Center, San Diego

94305

RECRUITING

Stanford Cancer Center, Stanford

94805

RECRUITING

Gustave Roussy, Villejuif

100142

ACTIVE_NOT_RECRUITING

Beijing University Cancer Hospital, Beijing

150081

RECRUITING

Harbin Medical University Cancer Hospital, Haerbin

200433

ACTIVE_NOT_RECRUITING

The Shanghai Pulmonary Hospital, Shanghai

276001

ACTIVE_NOT_RECRUITING

Linyi Cancer Hospital, Linyi

90025-6602

RECRUITING

The Angeles Clinic, Los Angeles

94143-2205

RECRUITING

University of California San Francisco, San Francisco

80218-1238

RECRUITING

Sarah Cannon Research Institute Denver, Denver

Unknown

RECRUITING

Institut Bergonie, Bordeaux

RECRUITING

Centre Leon Berard, Lyon

RECRUITING

APHM-CHU La Timone, Marseille

RECRUITING

CHU Nantes-Hotel Dieu, Nantes

RECRUITING

Arance, Barcelona

RECRUITING

NEXT Quirónsalud Madrid, Madrid

RECRUITING

H. Regional de Málaga, Málaga

RECRUITING

H. Virgen Macarena, Seville

RECRUITING

Berrocal, Valencia

RECRUITING

Hospital Quiron Dexeus, Barcelona

RECRUITING

Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria

RECRUITING

INCLIVA (Hospital Clinico de Valencia), Valencia

ACTIVE_NOT_RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT04913285 - A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Biotech Hunter | Biotech Hunter